TRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's DiseaseJennifer Zimmer,Paul Solomon,Cynthia D. Evans,Ming Lu,John R. Sims,Dawn A. Brooks,Mark A. MintunNEUROLOGY(2022)引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要